Synteract
Synteract is a full-service Contract Research Organization (CRO) focused on serving the emerging biopharma segment. Founded in 1986 and now operating as a Syneos Health company, it delivers clinical research services from its Morrisville, US base.
- Company typePrivate
- Founded1986
- HeadquartersMorrisville, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
Synteract firmographics
Firmographics- Name
- Synteract
- Website
- https://synteract.com
- Company type
- Private
- Founded year
- 1986
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Synteract is a full-service Contract Research Organization (CRO) focused on serving the emerging biopharma segment. Founded in 1986 and now operating as a Syneos Health company, it delivers clinical research services from its Morrisville, US base.
- Ownership category
- akta.pro rank
Synteract industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Functional Service Providers (FSP) & Resourcing CROs (HLAGAAAM)
Keywords
Where Synteract is headquartered
LocationHeadquarters
- HQ city
- Morrisville
- HQ country
- United States
- HQ region
- North America
Markets served
Synteract business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations
Synteract product offering
Product offeringCore offering
Synteract is a full-service contract research organization (CRO) providing clinical research and development services to the emerging biopharma segment. The company supports drug development sponsors across clinical trial design, execution, and regulatory activities. It operates as part of Syneos Health, extending CRO capabilities across the biopharmaceutical development lifecycle.
Differentiator
Problem solved
Functional benefit
Products and services
- Full-Service CRO Services End-to-end clinical research and development services for emerging biopharma sponsors, covering clinical trial management and related drug development support activities.
Companies that use Synteract
Customer profileIdeal customer profiles1 record
Synteract technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Synteract competitors and assessment
Company assessmentBroad incumbents
- Charles River Laboratories: Diversified CRO/preclinical services company with a clinical services segment overlapping Synteract's emerging-biopharma clinical trial offering, though most of its revenue is preclinical/manufacturing.
- Parexel: Large global CRO with strong emerging-biopharma and biopharma-services franchises. Comparable service portfolio (full-service clinical, FSP, biopharma-focused) at significantly larger scale.
- PPD (Thermo Fisher Scientific): Major clinical CRO now operating inside Thermo Fisher; directly overlaps Synteract's Phase I–IV clinical delivery and emerging-biopharma focus, but at vastly larger scale.
- ICON plc: One of the largest global CROs post-PRA acquisition. Comparable to Synteract as a clinical CRO serving biopharma across all phases, though materially larger and broader in scope.
- IQVIA: The largest global CRO/biopharma services platform with significant emerging-biopharma exposure. Comparable at the service-line level (clinical trials, FSP) but competes as a much broader incumbent.
Direct peers
- Clinipace Worldwide: Mid-sized, technology-forward CRO historically focused on small and mid-sized biopharma sponsors. Highly comparable in target customer, geographic reach, and full-service clinical positioning.
- Medpace: Mid-sized, full-service clinical CRO with a reputation for serving small and mid-sized biopharma sponsors. Directly comparable in target customer (emerging biopharma), therapeutic-area breadth, and mid-tier headcount profile.
- Worldwide Clinical Trials: Mid-sized, therapeutically focused CRO explicitly targeting mid- and small-cap biopharma. Comparable to Synteract in customer segment, study-phase focus (Phases I–IV), and mid-tier operating footprint.
Emerging players
- Celerion: Specialty early-phase clinical CRO strong in first-in-human and PK/biopharm work. Comparable as a niche biopharma-focused CRO, particularly in Phase I/early clinical — an adjacent segment Synteract covers.
- WuXi AppTec / WuXi Clinical: Global CRO/CDMO with an actively growing clinical services arm serving biotech sponsors. Comparable as a clinical CRO targeting biopharma, with particular overlap on China/U.S. cross-region trials.
Market position
Customer concentration
Synteract social profiles
Digital presenceSynteract financial estimates
Financial estimateRevenue estimate
Valuation estimate
Synteract leadership team
Management profileNumber of profiles
Profiles2 records
Synteract funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Synteract M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Synteract
What does Synteract do?
Synteract is a full-service contract research organization (CRO) providing clinical research and development services to the emerging biopharma segment. The company supports drug development sponsors across clinical trial design, execution, and regulatory activities. It operates as part of Syneos Health, extending CRO capabilities across the biopharmaceutical development lifecycle.
When was Synteract founded?
Synteract was founded in 1986. It employs 501 to 1,000 people.
Where is Synteract based?
Synteract is headquartered in Morrisville, United States, in the North America region.
Who are Synteract's main competitors?
Broad incumbents on record are Charles River Laboratories, Parexel, PPD (Thermo Fisher Scientific), ICON plc and IQVIA. Direct peers are Clinipace Worldwide, Medpace and Worldwide Clinical Trials. Emerging players are Celerion and WuXi AppTec / WuXi Clinical.
Does Synteract have an API?
No public API is recorded for Synteract.
What industry is Synteract in?
Synteract's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 8731.